|   N | Correlation coefficient | P value |
---|---|---|---|
a) Correlation with LDA (PtGA VAS score ≤ 20 mm) | |||
Mild Pain (VAS score ≤ 20 mm) | |||
 Tofacitinib 5 mg BID + csDMARDs |   695 | 0.74 | < 0.0001 |
 Placebo + csDMARDs |   366 | 0.73 | < 0.0001 |
Moderate Pain improvement (≥ 30% decrease from baseline) | |||
 Tofacitinib 5 mg BID + csDMARDs |   692 | 0.42 | < 0.0001 |
 Placebo + csDMARDs |   365 | 0.45 | < 0.0001 |
Substantial Pain improvement (≥ 50% decrease from baseline) | |||
 Tofacitinib 5 mg BID + csDMARDs |   692 | 0.55 | < 0.0001 |
 Placebo + csDMARDs |   365 | 0.58 | < 0.0001 |
HAQ-DI score ≥ normative value (≤ 0.25) | |||
 Tofacitinib 5 mg BID + csDMARDs |   695 | 0.28 | < 0.0001 |
 Placebo + csDMARDs |   366 | 0.24 | < 0.0001 |
HAQ-DI change ≥ MCID (≥ 0.22 improvement from baseline) | |||
 Tofacitinib 5 mg BID + csDMARDs |   693 | 0.18 | < 0.0001 |
 Placebo + csDMARDs |   364 | 0.14 | 0.0064 |
FACIT-F score ≥ normative value (≥ 43.5) | |||
 Tofacitinib 5 mg BID + csDMARDs |   694 | 0.35 | < 0.0001 |
 Placebo + csDMARDs |   365 | 0.29 | < 0.0001 |
FACIT-F change ≥ MCID (≥ 4.0 improvement from baseline) | |||
 Tofacitinib 5 mg BID + csDMARDs |   693 | 0.13 | 0.0004 |
 Placebo + csDMARDs |   363 | 0.11 | 0.0413 |
b) Correlation with moderate PtGA improvement (≥ 30% decrease from baseline) | |||
Mild Pain (VAS score ≤ 20 mm) | |||
 Tofacitinib 5 mg BID + csDMARDs |   694 | 0.42 | < 0.0001 |
 Placebo + csDMARDs |   365 | 0.42 | < 0.0001 |
Moderate Pain improvement (≥ 30% decrease from baseline) | |||
 Tofacitinib 5 mg BID + csDMARDs |   692 | 0.64 | < 0.0001 |
 Placebo + csDMARDs |   365 | 0.55 | < 0.0001 |
Substantial Pain improvement (≥ 50% decrease from baseline) | |||
 Tofacitinib 5 mg BID + csDMARDs |   692 | 0.56 | < 0.0001 |
 Placebo + csDMARDs |   365 | 0.55 | < 0.0001 |
HAQ-DI score ≥ normative value (≤ 0.25) | |||
 Tofacitinib 5 mg BID + csDMARDs |   694 | 0.13 | 0.0006 |
 Placebo + csDMARDs |   365 | 0.16 | 0.0029 |
HAQ-DI change ≥ MCID (≥ 0.22 improvement from baseline) | |||
 Tofacitinib 5 mg BID + csDMARDs |   692 | 0.30 | < 0.0001 |
 Placebo + csDMARDs |   364 | 0.30 | < 0.0001 |
FACIT-F score ≥ normative value (≥ 43.5) | |||
 Tofacitinib 5 mg BID + csDMARDs |   693 | 0.17 | < 0.0001 |
 Placebo + csDMARDs |   364 | 0.18 | 0.0008 |
FACIT-F change ≥ MCID (≥ 4.0 improvement from baseline) | |||
 Tofacitinib 5 mg BID + csDMARDs |   692 | 0.24 | < 0.0001 |
 Placebo + csDMARDs |   363 | 0.26 | <  0.0001 |
c) Correlation with substantial PtGA improvement (≥ 50% decrease from baseline) | |||
Mild Pain (VAS score ≤ 20 mm) | |||
 Tofacitinib 5 mg BID + csDMARDs |   694 | 0.55 | < 0.0001 |
 Placebo + csDMARDs |   365 | 0.50 | < 0.0001 |
Moderate Pain improvement (≥ 30% decrease from baseline) | |||
 Tofacitinib 5 mg BID + csDMARDs |   692 | 0.59 | < 0.0001 |
 Placebo + csDMARDs |   365 | 0.51 | < 0.0001 |
Substantial Pain improvement (≥ 50% decrease from baseline) | |||
 Tofacitinib 5 mg BID + csDMARDs |   692 | 0.68 | < 0.0001 |
 Placebo + csDMARDs |   365 | 0.70 | < 0.0001 |
HAQ-DI score ≥ normative value (≤ 0.25) | |||
 Tofacitinib 5 mg BID + csDMARDs |   694 | 0.18 | < 0.0001 |
 Placebo + csDMARDs |   365 | 0.13 | 0.0126 |
HAQ-DI change ≥ MCID (≥ 0.22 improvement from baseline) | |||
 Tofacitinib 5 mg BID + csDMARDs |   692 | 0.29 | < 0.0001 |
 Placebo + csDMARDs |   364 | 0.26 | < 0.0001 |
FACIT-F score ≥ normative value (≥ 43.5) | |||
 Tofacitinib 5 mg BID + csDMARDs |   693 | 0.23 | < 0.0001 |
 Placebo + csDMARDs |   364 | 0.20 | 0.0001 |
FACIT-F change ≥ MCID (≥ 4.0 improvement from baseline) | |||
 Tofacitinib 5 mg BID + csDMARDs |   692 | 0.26 | < 0.0001 |
 Placebo + csDMARDs |   363 | 0.23 | < 0.0001 |